Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results from ERCHIVES

Clinical Infectious Diseases

Volumn 65, Issue 1, 2017, Pages 64-72

  Butt, Adeel A ^a,b,c   Ren, Yanjie ^a   Lo Re, Vincent ^d   Taddei, Tamar H ^e,f   Kaplan, David E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c HAMAD MEDICAL CORPORATION   (Qatar)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ERCHIVES; HCV; mortality; outcomes; treatment

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; ARTICLE; CHILD PUGH SCORE; CLINICAL EVALUATION; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DECOMPENSATED LIVER CIRRHOSIS; DIGESTIVE SYSTEM DISEASE ASSESSMENT; FEMALE; FIB 4 SCORE; HEPATITIS C; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; VETERAN; COHORT ANALYSIS; KAPLAN MEIER METHOD; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85021835147     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix224     Document Type: Article

References (32)

1. Afdhal N, Zeuzem S, Kwo P, et al. ; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-98.
2. Afdhal N, Reddy KR, Nelson DR, et al. ; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93.
3. Ferenci P, Bernstein D, Lalezari J, et al. ; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983-92.
4. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-82.
5. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study. Lancet 2015; 386:1537-45.
6. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial. Ann Intern Med 2015; 163:1-13.
7. Cho HC, Jung HY, Sinn DH, et al. Mortality after surgery in patients with liver cirrhosis: Comparison of Child-Turcotte-Pugh, MELD and MELDNa score. Eur J Gastroenterol Hepatol 2011; 23:51-9.
8. Chawla YK, Kashinath RC, Duseja A, Dhiman RK. Predicting mortality across a broad spectrum of liver disease-an assessment of model for end-stage liver disease (MELD), child-turcotte-pugh (CTP), creatinine-modified CTP scores. J Clin Exp Hepatol 2011; 1:161-8.
9. Choi PC, Kim HJ, Choi WH, et al. Model for end-stage liver disease, model for end-stage liver disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of complications of liver cirrhosis. Liver Int 2009; 29:221-6.
10. Farnsworth N, Fagan SP, Berger DH, Awad SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 2004; 188:580-3.
11. Sterling RK, Lissen E, Clumeck N, et al. ; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25.
12. Park LS, Tate JP, Justice AC, et al. FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev 2011; 20:2512-7.
13. Lo Re V, 3rd, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med 2014; 160:369-79.
14. Lo Re V, 3rd, Kallan MJ, Tate JP, et al. Predicting risk of end-stage liver disease in antiretroviral-treated human immunodeficiency virus/hepatitis C virus-coinfected patients. Open forum infectious diseases 2015; 2:ofv109.
15. Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB; ERCHIVES study team. Changes in circulating lipids level over time after acquiring HCV infection: Results from ERCHIVES. BMC Infect Dis 2015; 15:510.
16. Butt AA, Yan P, Lo Re V 3rd, et al. ; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015; 175:178-85.
17. Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology 2016; 64:47-57.
18. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE; ERCHIVES study. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: Results from ERCHIVES. Liver Int 2016; 36:651-8.
19. Rogal SS, Yan P, Rimland D, et al. ; Electronically Retrieved Cohort of HCV Infected Veterans Study Group. Incidence and progression of chronic kidney disease after hepatitis C seroconversion: Results from ERCHIVES. Dig Dis Sci 2016; 61:930-6.
20. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-26.
21. Kaplan DE, Dai F, Aytaman A, et al. Development and performance of an algorithm to estimate the child-turcotte-pugh score from a national electronic healthcare database. Clin Gastroenterol Hepatol 2015; 13:2333-41. e1-6.
22. Lo RV, III, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the veterans aging cohort study. Pharmacoepidemiol Drug Saf 2011; 20:689-99.
23. Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology 2016; 64:47-57.
24. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre-A nd post-HAART and the role of HCV coinfection. Hepatology 2004; 40:115-9.
25. Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. ; Veterans Aging Cohort Study. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23:1227-34.
26. Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis 2011; 57:396-402.
27. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49:225-32.
28. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC; Veterans Aging Cohort 5 Project Team. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006; 130:1326-33.
29. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kent Kwoh C. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007; 14:890-6.
30. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36(5 Suppl 1):S74-83.
31. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131:174-81.
32. Graham J. VA extends new hepatitis C drugs to all veterans in its health system. JAMA 2016; Published online August 10, 2016. doi:10. 1001/jama. 2016. 8669. Accessed 23 December 2016.